LVTX | LAVA Therapeutics NV
Next ER: February 22, 2023 After Market Closes
LAVA Therapeutics N.V. is developing a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary Gammabody? platform. The company?s innovative approach leverages bispecific antibodies to activate V?9V?2 T cells upon binding to membrane-expressed tumor associated antigens. Activated V?9V?2 T cells are engaged for direct, selective tumor cell killing. The company?s two lead programs, LAVA-051 and LAVA-1207, are both presently enrolling patients in Phase 1/2a clinical studies. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.
More profiles and info about the company
News for (LVTX)
This company doesn't provide a dividend.
Talk about LAVA Therapeutics NV below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
( FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
Support this project
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Very few careers can offer you the freedom, flexibility, and income that day trading does. As a day trader, you can live and work anywhere in the world. You can decide when to work and when not to work. You only answer to yourself. That is the life of the successful day trader. Many people aspire to it, but very few succeed.
A Beginner's Guide to Trading Tools and Tactics, Money Management, Discipline and Trading Psychology